Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients

S. F L Van Lelyveld; J. Symons; P. Van Ham; B. J. Connell; M. Nijhuis; A. M J Wensing; A. I M Hoepelman

doi:10.1016/j.ijantimicag.2015.09.013

Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients

S. F L Van Lelyveld^*, J. Symons, P. Van Ham, B. J. Connell, M. Nijhuis, A. M J Wensing, A. I M Hoepelman

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Available data on the use of maraviroc (MVC) in clinical settings are limited. In this cohort study, the clinical outcomes of HIV-1-infected patients treated with MVC were analysed and the predictive values of different tropism assays were compared. Baseline viral tropism was assessed and compared by phenotypic (Trofile and MT-2) and genotypic assays. Virological and immunological responses were evaluated. In total, 62 predominantly extensively pre-treated patients started MVC [median GSS 2.0 (IQR 2.0-2.5)]. Tropism assays were performed on baseline samples of 58 patients (93.5%). Thirty-two samples (80.0%) were classified as R5 by Trofile, 41 (80.4%) by genotypic tropism test (GTT) and 17 (81.0%) by MT-2. At least two types of tropism assay were performed on samples from 39 patients, whereas in 15 patients all three assays were performed (concordance 84.8-94.1%). Plasma HIV-RNA was

Original language	English
Pages (from-to)	84-90
Number of pages	7
Journal	International Journal of Antimicrobial Agents
Volume	47
Issue number	1
DOIs	https://doi.org/10.1016/j.ijantimicag.2015.09.013
Publication status	Published - 1 Jan 2016

Keywords

CCR5 antagonist
HIV Infection
Human immunodeficiency virus
Maraviroc
Tropism

Access to Document

10.1016/j.ijantimicag.2015.09.013

Cite this

@article{0f500322ec274abca8a3b611bbb97dbb,

title = "Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients",

abstract = "Available data on the use of maraviroc (MVC) in clinical settings are limited. In this cohort study, the clinical outcomes of HIV-1-infected patients treated with MVC were analysed and the predictive values of different tropism assays were compared. Baseline viral tropism was assessed and compared by phenotypic (Trofile and MT-2) and genotypic assays. Virological and immunological responses were evaluated. In total, 62 predominantly extensively pre-treated patients started MVC [median GSS 2.0 (IQR 2.0-2.5)]. Tropism assays were performed on baseline samples of 58 patients (93.5%). Thirty-two samples (80.0%) were classified as R5 by Trofile, 41 (80.4%) by genotypic tropism test (GTT) and 17 (81.0%) by MT-2. At least two types of tropism assay were performed on samples from 39 patients, whereas in 15 patients all three assays were performed (concordance 84.8-94.1%). Plasma HIV-RNA was ",

keywords = "CCR5 antagonist, HIV Infection, Human immunodeficiency virus, Maraviroc, Tropism",

author = "{Van Lelyveld}, {S. F L} and J. Symons and {Van Ham}, P. and Connell, {B. J.} and M. Nijhuis and Wensing, {A. M J} and Hoepelman, {A. I M}",

year = "2016",

month = jan,

day = "1",

doi = "10.1016/j.ijantimicag.2015.09.013",

language = "English",

volume = "47",

pages = "84--90",

journal = "International Journal of Antimicrobial Agents",

issn = "0924-8579",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients

AU - Van Lelyveld, S. F L

AU - Symons, J.

AU - Van Ham, P.

AU - Connell, B. J.

AU - Nijhuis, M.

AU - Wensing, A. M J

AU - Hoepelman, A. I M

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Available data on the use of maraviroc (MVC) in clinical settings are limited. In this cohort study, the clinical outcomes of HIV-1-infected patients treated with MVC were analysed and the predictive values of different tropism assays were compared. Baseline viral tropism was assessed and compared by phenotypic (Trofile and MT-2) and genotypic assays. Virological and immunological responses were evaluated. In total, 62 predominantly extensively pre-treated patients started MVC [median GSS 2.0 (IQR 2.0-2.5)]. Tropism assays were performed on baseline samples of 58 patients (93.5%). Thirty-two samples (80.0%) were classified as R5 by Trofile, 41 (80.4%) by genotypic tropism test (GTT) and 17 (81.0%) by MT-2. At least two types of tropism assay were performed on samples from 39 patients, whereas in 15 patients all three assays were performed (concordance 84.8-94.1%). Plasma HIV-RNA was

AB - Available data on the use of maraviroc (MVC) in clinical settings are limited. In this cohort study, the clinical outcomes of HIV-1-infected patients treated with MVC were analysed and the predictive values of different tropism assays were compared. Baseline viral tropism was assessed and compared by phenotypic (Trofile and MT-2) and genotypic assays. Virological and immunological responses were evaluated. In total, 62 predominantly extensively pre-treated patients started MVC [median GSS 2.0 (IQR 2.0-2.5)]. Tropism assays were performed on baseline samples of 58 patients (93.5%). Thirty-two samples (80.0%) were classified as R5 by Trofile, 41 (80.4%) by genotypic tropism test (GTT) and 17 (81.0%) by MT-2. At least two types of tropism assay were performed on samples from 39 patients, whereas in 15 patients all three assays were performed (concordance 84.8-94.1%). Plasma HIV-RNA was

KW - CCR5 antagonist

KW - HIV Infection

KW - Human immunodeficiency virus

KW - Maraviroc

KW - Tropism

UR - http://www.scopus.com/inward/record.url?scp=84953776115&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2015.09.013

DO - 10.1016/j.ijantimicag.2015.09.013

M3 - Article

C2 - 26585497

AN - SCOPUS:84953776115

SN - 0924-8579

VL - 47

SP - 84

EP - 90

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

IS - 1

ER -

Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this